Role of complement in inflammation and injury in the nervous system

Experimental and Clinical Immunogenetics

Volumn 14, Issue 1, 1997, Pages 19-23

  Morgan, B Paul ^a   Gasque, Philippe ^a   Singhrao, Sim K ^a   Piddlesden, Sara J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cerebral trauma; Complement; Demyelination; Nervous system; Neurodegeneration

Indexed keywords

COMPLEMENT; COMPLEMENT RECEPTOR;

BLOOD BRAIN BARRIER; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DEMYELINATION; HUMAN; IMMUNITY; NERVE DEGENERATION; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; STROKE;

ANIMALS; BRAIN; BRAIN INJURIES; COMPLEMENT SYSTEM PROTEINS; DEMYELINATING DISEASES; HUMANS; INFLAMMATION; NERVE DEGENERATION; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEUROIMMUNOMODULATION; RECEPTORS, COMPLEMENT; TRAUMA, NERVOUS SYSTEM;

EID: 0030974933     PISSN: 02549670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Morgan BP: Physiology and pathophysiology of complement: Progress and trends. Crit Rev Clin Lab Sci 1995;32:265-298.
2. Prineas JW, Wright RG: Macrophages, lymphocytes and plasma cells in the penvascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-421.
3. Ryberg B: Anti-brain antibodies in multiple sclerosis: Relation to clinical variables. J Neurol Sci 1982;54: 239-261.
4. Link H: Complement factors in multiple sclerosis. Acta Neurol Scand 1972;48:521-528.
5. Mollnes TE, Vandvick B, Lea T, Vandal F: Imrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 1987;78:17-28.
6. Compston DAS, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B: Immunocytochemical localisation of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316.
7. Piddlesden SJ, Lassmann H, Zimpnch F, Morgan BP, Linington C: The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-564.
8. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP: Soluble complement receptor 1 (sCR1) inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis (AD-EAE). J Immunol 1994;152:5477-5484.
9. Piddlesden SJ, Morgan BP: Killing of rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J Neuroimmunol 1993;48:169-176.
10. Koski CL, Gratz E, Sutherland J, Mayer RF: Clinical correlation with anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1986;19:573-577.
11. Nyland H, Aarli JA: Guillain-Barré syndrome: Demonstration of antibodies to peripheral nerve tissue. Acta Neurol Scand 1978;58:35-43.
12. Koski CL, Sander ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA: Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. J Clin Invest 1987;80: 1492-1497.
13. Monaco S, Bonetti B, Ferrari S, et al: Complement-mediated demyelination in patients with IgM monoclonal gammopathy and peripheral neuropathy. N Engl J Med 1990; 322:649-652.
14. Rogers J, Schultz J, Brachova L, Lue LF, Webster S, Bradt B, Cooper NR, Moss DE: Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol 1992;143:624-630.
15. Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM: Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab 1995; 15:860-864.
16. Ostergard JR, Kristensen BO, Svehag SE, Teisner B, Militec T: Immune complexes and complement activation following rupture of intracranial saccular aneurysms. J Neurosurg 1987;66:891-897.
17. Czurko A, Nishino H: Appearance of immunoglobulin G and complement factor C3 in the striatum after transient focal ischaemia in the rat. Neurosci Lett 1994; 166:51-54.
18. Morgan BP, Gasque P: Expression of complement in the brain: Role in health and disease. Immunol Today 1996;17:461-465.
19. Barnum SR: Biosynthesis and regulation of complement by cells of the central nervous system. Compl Today 1993;1:76-95.
20. Levi-Strauss M, Mallat M: Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol 1987;139:2361-2366.
21. Fearon DT: Anti-inflammatory and immunosuppressive effects of recombmant soluble complement receptors. Clin Exp Immunol 1991; 86(suppl 1):43-46.
22. Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP: Soluble complement receptor 1 (sCRI) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol, in press.